Active, not recruitingPHASE1, PHASE2NCT06137742
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-07868489(drug)
- Enrollment
- 97 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Anaheim Clinical Trials, LLC, Anaheim, California, United States
- UCI Health - Costa Mesa, Costa Mesa, California, United States
- UCI Health Center for Innovative Health Therapies (CIHT), Orange, California, United States
- University of California, Irvine Medical Center, Orange, California, United States
- UC Davis Health Medical Center, Sacramento, California, United States
- University of California Davis Health, Sacramento, California, United States
- UCSF Health St. Mary's Hospital, San Francisco, California, United States
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Norton Hospital, Louisville, Kentucky, United States
- Norton Pulmonary Specialists, Louisville, Kentucky, United States
- Icahn school of medicine at Mount Sinai, New York, New York, United States
- Mount Sinai Hospital, New York, New York, United States
- Eastowne 100 Medical Office Building, Chapel Hill, North Carolina, United States
- Eastowne Medical Office Building - Clinical Research Unit, Chapel Hill, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06137742 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →